The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $603,338 Project Grant to Yale University. The grant supports research to understand how the human immunodeficiency virus 1 (HIV-1) mediates fusion with host cells, specifically investigating the interactions between the viral envelope glycoprotein (Env), cellular receptors CD4 and CCR5/CXCR4, and cell membranes. Using...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Program (CFDA 93.855), provides $653,693 to Emory University to conduct research on the structural details of HIV-1 virion assembly, maturation, and entry. The work will leverage cryo-electron microscopy and tomography to interrogate the molecular determinants and cellular interactions involved in the HIV-1 capsid lattice formation and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $847,141 to investigate the role of HIV-1 integrase (IN) in virion morphogenesis and target it with novel allosteric integrase inhibitors. The research aims to delineate the sequence and structural features of viral RNA recognized by HIV-1 IN and determine cryo-EM structures of IN tetramers bound to cognate viral RNA...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $617,376 to Emory University to conduct research on the activation and maturation of the HIV-1 virus. The key objectives are to: 1) Measure the timing of protease (PR) activation relative to HIV-1 budding from the host cell, 2) Assess the rate and extent of PR substrate cleavage and correlate this with formation of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $859,992 to Yale University to conduct research on the molecular mechanisms underlying HIV-1 maturation and the impact of capsid inhibitors on this process. The research aims to: 1) determine the high-resolution structural pathway of HIV-1 Gag assemblies and capsid during maturation within their native...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $220,224 to the University of Chicago to computationally investigate key morphological transitions in the HIV-1 life cycle. The research aims to gain a deeper mechanistic understanding of HIV assembly, maturation, and uncoating processes, with a focus on the roles of viral RNA, host cell factors, and...
This Project Grant award of $229,163 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research on the function of the HIV-1 envelope glycoprotein cytoplasmic tail domain. The goal is to investigate how modifications to the cytoplasmic tail, such as lipidation, impact the trafficking and packaging of the envelope protein into HIV-1 virions, which could enable viral spread in restrictive cell types. The research plan...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to better understand the molecular mechanisms of HIV spread through cell-cell contact across a virological synapse (VS). The $515,282 award will enable Case Western Reserve University (CWRU) to develop a novel flow cytometry assay for quantifying and purifying infected cell-target cell pairs, and leverage...
The federal Project Grant award R01AI187016 for $737,761.00, awarded on August 1, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (TFH) cells, which are essential for vigorous B cell activity within germinal centers, to facilitate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $910,905.00 to the Scripps Research Institute to advance HIV vaccine development using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
HIV-1 MEMBRANE FUSION AND INHIBITION - SUMMARY VIRUS ENTRY BEGINS WITH THE FIRST ENCOUNTER BETWEEN THE VIRUS AND THE CELL SURFACE AND ENDS WITH DELIVERY OF THE CONTENTS OF THE VIRUS INTO THE HOST CELL. HIV-1 MEMBRANE FUSION IS THE FIRST KEY DELIVERY STEP, MEDIATED BY THE VIRUS-ENCODED ENVELOPE GLYCOPROTEIN [ENV; TRIMERIC (GP160)3 CLEAVED TO (GP120/GP41)3], WHICH BELONGS TO THE GROUP OF CLASS I VIRAL FUSION PROTEINS INCLUDING INFLUENZA HEMAGGLUTININ, SARS-COV-2 SPIKE PROTEIN AND EBOLA GLYCOPROTEIN. A MATURE ENV SPIKE HAS THREE COPIES EACH OF NONCOVALENTLY-ASSOCIATED RECEPTOR-BINDING SUBUNIT GP120 AND FUSION SUBUNIT GP41. SEQUENTIAL BINDING OF GP120 TO THE PRIMARY RECEPTOR CD4 AND A CORECEPTOR (CHEMOKINE RECEPTOR CCR5 OR CXCR4) LEADS TO LARGE, IRREVERSIBLE STRUCTURAL REARRANGEMENTS IN GP41, WHICH DRIVE FUSION. THIS PICTURE, DERIVED LARGELY FROM STRUCTURAL STUDIES OF THE SOLUBLE FRAGMENTS AND FROM CELLULAR STUDIES WITH INHIBITORS AND ANTIBODIES, IS STILL INCOMPLETE BECAUSE IT LACKS EXTENSION TO A HIGH-RESOLUTION PICTURE OF THE COMPLETE ENV TRIMER IN THE CONTEXT OF A LIPID-BILAYER MEMBRANE, WHICH IS THE SUBSTRATE OF THE FUSION REACTION. WE HAVE DETERMINED BY NMR THE STRUCTURES OF THE HIV-1 ENV TRANSMEMBRANE DOMAIN (TMD), MEMBRANE PROXIMAL EXTERNAL REGION (MPER), AND CYTOPLASMIC TAIL (CT) IN BICELLES THAT MIMIC LIPID BILAYERS. THESE REGIONS ALL FORM WELL-ORDERED, TRIMERIC CLUSTERS IN A LIPID BILAYER. DISRUPTION OF ANY OF THEM CAN REDUCE MEMBRANE FUSION EFFICIENCY AND ALTER THE ANTIGENIC STRUCTURE OF THE ENTIRE ENV, SUGGESTING THAT THEY HAVE STRUCTURAL AND FUNCTIONAL ROLES IN FUSION AND IN TRIMER CONFORMATIONAL STABILIZATION. VERY RECENTLY, WE HAVE COMPLETED A HIGH-RESOLUTION STRUCTURE OF THE INTACT SARS-COV-2 POSTFUSION SPIKE IN MEMBRANE, SHOWING HOW THE FUNCTIONALLY CRITICAL MEMBRANE-INTERACTING REGIONS INTERACT WITH MEMBRANE AND WITH EACH OTHER. THESE FINDINGS ARE THE BASIS OF OUR OVERALL HYPOTHESIS THAT THAT STRUCTURES OF THE HIV-1 FUSION COMPLEX EITHER ALONE OR BOUND WITH FUSION INHIBITORS IN MEMBRANE WILL REVEAL NEW STRUCTURAL FEATURES OF THE MEMBRANE-INTERACTING REGIONS AND SUBSTANTIALLY ADVANCE OUR MECHANISTIC UNDERSTANDING OF THE VIRAL FUSION AND ITS INHIBITION, THEREBY INFORMING FUTURE DEVELOPMENT OF INTERVENTION STRATEGIES. WE WILL APPLY ADVANCED TECHNOLOGIES IN CRYOGENIC ELECTRON MICROSCOPY (CRYO-EM) AND TOMOGRAPHY (CRYO-ET) TO STUDY STRUCTURAL AND FUNCTIONAL PROPERTIES OF THE HIV-1 FUSION COMPLEX, AS RECONSTITUTED IN MEMBRANES AND ON THE SURFACE OF A VIRUS PARTICLE. WE WILL ALSO INVESTIGATE MOLECULAR MECHANISMS OF HIV-1 INHIBITION BY TWO DISTINCT TYPES OF FUSION INHIBITORS. OUR GOAL IS A "MOLECULAR MOVIE" OF HIV-1 FUSION, TO INFORM DEVELOPMENT OF NEW INTERVENTION STRATEGIES. WE PROPOSE THE FOLLOWING SPECIFIC AIMS TO ADDRESS OUR HYPOTHESIS: 1) WE WILL DETERMINE STRUCTURE OF THE HIV-1 FUSION COMPLEX CONTAINING INTACT ENV, CD4 AND CCR5 IN THE CONTEXT OF A LIPID BILAYER. 2) WE WILL INVESTIGATE MOLECULAR MECHANISM OF HIV-1 FUSION INHIBITION BY ANTI-CD4 ANTIBODY IBALIZUMAB. 3) WE WILL DISSECT MECHANISM OF ACTION OF SMALL-MOLECULE FUSION INHIBITORS TARGETING THE MPER OF HIV-1 ENV.